Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (Ab168381)

特异性

This antibody only detects alpha Synuclein phosphorylated on Ser129.

Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, WB in human samples. Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) has been cited over 40 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Alpha-synuclein (phospho S129) antibody (Anti-pS129 alpha-synuclein antibody) [MJF-R13 (8-8)] (ab168381) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) has 4 independent reviews from customers. Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) specifically detects Alpha-synuclein Phospho-S129 (UniProt ID: P37840; Molecular weight: 14kDa) and is sold in 100 µL and 1 mL selling sizes. Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) was developed by Abcam in partnership with the Michael J. Fox Foundation for Parkinson's Research. Alpha-synuclein phosphorylated at serine 129 (pS129; SNCA/NACP) is a key pathological marker in neurodegenerative diseases such as Parkinson's disease. This phosphorylation event is associated with the abnormal aggregation of alpha-synuclein into Lewy bodies, which are indicative of disease. Studies have shown that pS129 not only promotes the aggregation of alpha-synuclein but also increases its neurotoxicity, contributing to neuronal death and disease progression Alpha-synuclein was the first gene to be linked to Parkinson's disease (PD) and remains the most promising link to PD pathogenesis, where there is genetic evidence that it may play a causal role. In the brain, alpha-synuclein is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. Recent studies also indicate that alpha-synuclein undergoes post-translational modification. Though the role of many of these modifications is still under investigation, phosphorylation at Serine 129 may affect alpha-synuclein aggregations and may also serve as marker of disease pathogenesis. With the advent of this phospho-specific Serine 129 antibody, The Michael J. Fox Foundation hopes to ensure that the putative role of this modification can be further examined by all researchers. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Collaborations This antibody was developed with support from The Michael J. Fox Foundation.